Effectiveness of mid-regional pro-adrenomedullin, compared to other biomarkers (including lymphocyte subpopulations and immunoglobulins), as a prognostic biomarker in COVID-19 critically ill patients: New evidence from a 15-month observational prospective study.

Giorgia Montrucchio,Gabriele Sales,Eleonora Balzani,Davide Lombardo,Alice Giaccone,Giulia Cantù,Giulia D'Antonio,Francesca Rumbolo,Silvia Corcione,Umberto Simonetti,Chiara Bonetto,Marinella Zanierato,Vito Fanelli,Claudia Filippini,Giulio Mengozzi,Luca Brazzi

Frontiers in medicine（2023）

引用 2|浏览14

暂无评分

摘要

MR-proADM seems to be the best biomarker for the stratification of mortality risk in critically ill patients with COVID-19. The Ig levels and lymphocyte subpopulations (except for natural killers) seem not to be correlated with mortality. Larger, multicentric studies are needed to confirm these findings.

查看译文

关键词

COVID-19,MR-proADM,SARS-CoV-2,adrenomedullin,biomarkers,immunoglobulins,intensive care,lymphocyte subpopulations

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要